We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
Read MoreHide Full Article
Shares of PDS Biotechnology Corporation (PDSB - Free Report) were up 23.8% on Dec 28 after management announced interim data from a phase II study, which evaluated a PDS0101-based triple combination therapy in checkpoint inhibitor (CPI)-naïve and CPI-refractory patients with advanced human papillomavirus (HPV)-positive cancers.
The PDS0101-based triple combination therapy consisted of PDS Biotech’s lead pipeline candidate PDS0101, tumor-targeting IL-12 fusion protein M9241 and a bifunctional fusion protein targeting two independent immunosuppressive pathways (PD-L1 and TGF-β), bintrafusp alfa.
Data from the study achieved a median overall survival (OS) of 21 months in 29 checkpoint inhibitor (CPI) refractory HPV16-positive cancer patients who received the triple combination therapy. Per management, the historical median OS in patients with CPI refractory disease is 3-4 months. In CPI-naïve patients, the median OS is yet to be reached as 75% of patients remain alive at a median follow-up of 27 months.
While the objective response rate (ORR) in CPI-refractory patients administered an optimal dose of the triple dose combination was 63%, the ORR in CPI-naïve patients was 88%. Per management, the current approaches have achieved ORRs of less than 10% and 25% in CPI-refractory and CPI- naïve patients, respectively.
Shares of PDS Biotech have lost 40.7% in the year against the industry’s 22.1% decline.
Image Source: Zacks Investment Research
Based on the above data, PDS Biotech intends to discuss its next steps and plans for a registrational study evaluating this PDS0101-based triple combination therapy.
All patients enrolled in this phase II study had failed prior treatment with chemotherapy and 90% had failed radiation treatment. We note that the study is being conducted by the National Cancer Institute (NCI), one of the Institutes of the National Institutes of Health (NIH).
PDS Biotech currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector include Acer Therapeutics (ACER - Free Report) , Amylyx Pharmaceuticals (AMLX - Free Report) and Can-Fite BioPharma (CANF - Free Report) . While Acer Therapeutics sports a Zacks Rank #1 (Strong Buy), Amylyx Pharmaceuticals and Can-Fite BioPharma carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Acer Therapeutics’ 2022 loss per share have narrowed from $2.47 to $1.50. During the same period, the loss estimates per share for 2023 have narrowed from $1.07 to 61 cents. Shares of Acer Therapeutics have risen 12.7% year-to-date.
Earnings of Acer Therapeutics beat estimates in two of the last four quarters and missed the mark twice, witnessing a negative earnings surprise of 95.82%, on average. In the last reported quarterAcer Therapeutics’ earnings beat estimates by 59.21%.
In the past 60 days, estimates for Amylyx Pharmaceuticals’ 2022 loss per share have narrowed from $3.54 to $3.53. During the same period, the loss estimates per share for 2023 have narrowed from 65 cents to 60 cents. Shares of Amylyx Pharmaceuticals have surged 93.4% in the year-to-date period.
Earnings of Amylyx Pharmaceuticals missed estimates in two of the last three quarters and beat the mark once, witnessing a negative earnings surprise of 6.65%, on average. In the last reported quarter, Amylyx Pharmaceuticals’ earnings beat estimates by 5.15%.
In the past 60 days, estimates for Can-Fite BioPharma’s 2022 loss per share have narrowed from 37 cents to 28 cents. During the same period, the loss estimates per share for 2023 have narrowed from 17 cents to 12 cents. Shares of Can-Fite BioPharma have declined 49.7% in the year-to-date period.
Earnings of Can-Fite BioPharma beat estimates in three of the last four quarters and missed the mark once, witnessing a earnings surprise of 10.14%, on average. In the last reported quarter, Can-Fite BioPharma’s earnings beat estimates by 10.00%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
Shares of PDS Biotechnology Corporation (PDSB - Free Report) were up 23.8% on Dec 28 after management announced interim data from a phase II study, which evaluated a PDS0101-based triple combination therapy in checkpoint inhibitor (CPI)-naïve and CPI-refractory patients with advanced human papillomavirus (HPV)-positive cancers.
The PDS0101-based triple combination therapy consisted of PDS Biotech’s lead pipeline candidate PDS0101, tumor-targeting IL-12 fusion protein M9241 and a bifunctional fusion protein targeting two independent immunosuppressive pathways (PD-L1 and TGF-β), bintrafusp alfa.
Data from the study achieved a median overall survival (OS) of 21 months in 29 checkpoint inhibitor (CPI) refractory HPV16-positive cancer patients who received the triple combination therapy. Per management, the historical median OS in patients with CPI refractory disease is 3-4 months. In CPI-naïve patients, the median OS is yet to be reached as 75% of patients remain alive at a median follow-up of 27 months.
While the objective response rate (ORR) in CPI-refractory patients administered an optimal dose of the triple dose combination was 63%, the ORR in CPI-naïve patients was 88%. Per management, the current approaches have achieved ORRs of less than 10% and 25% in CPI-refractory and CPI- naïve patients, respectively.
Shares of PDS Biotech have lost 40.7% in the year against the industry’s 22.1% decline.
Image Source: Zacks Investment Research
Based on the above data, PDS Biotech intends to discuss its next steps and plans for a registrational study evaluating this PDS0101-based triple combination therapy.
All patients enrolled in this phase II study had failed prior treatment with chemotherapy and 90% had failed radiation treatment. We note that the study is being conducted by the National Cancer Institute (NCI), one of the Institutes of the National Institutes of Health (NIH).
PDS Biotechnology Corporation Price
PDS Biotechnology Corporation price | PDS Biotechnology Corporation Quote
Zacks Rank & Stocks to Consider
PDS Biotech currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector include Acer Therapeutics (ACER - Free Report) , Amylyx Pharmaceuticals (AMLX - Free Report) and Can-Fite BioPharma (CANF - Free Report) . While Acer Therapeutics sports a Zacks Rank #1 (Strong Buy), Amylyx Pharmaceuticals and Can-Fite BioPharma carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Acer Therapeutics’ 2022 loss per share have narrowed from $2.47 to $1.50. During the same period, the loss estimates per share for 2023 have narrowed from $1.07 to 61 cents. Shares of Acer Therapeutics have risen 12.7% year-to-date.
Earnings of Acer Therapeutics beat estimates in two of the last four quarters and missed the mark twice, witnessing a negative earnings surprise of 95.82%, on average. In the last reported quarterAcer Therapeutics’ earnings beat estimates by 59.21%.
In the past 60 days, estimates for Amylyx Pharmaceuticals’ 2022 loss per share have narrowed from $3.54 to $3.53. During the same period, the loss estimates per share for 2023 have narrowed from 65 cents to 60 cents. Shares of Amylyx Pharmaceuticals have surged 93.4% in the year-to-date period.
Earnings of Amylyx Pharmaceuticals missed estimates in two of the last three quarters and beat the mark once, witnessing a negative earnings surprise of 6.65%, on average. In the last reported quarter, Amylyx Pharmaceuticals’ earnings beat estimates by 5.15%.
In the past 60 days, estimates for Can-Fite BioPharma’s 2022 loss per share have narrowed from 37 cents to 28 cents. During the same period, the loss estimates per share for 2023 have narrowed from 17 cents to 12 cents. Shares of Can-Fite BioPharma have declined 49.7% in the year-to-date period.
Earnings of Can-Fite BioPharma beat estimates in three of the last four quarters and missed the mark once, witnessing a earnings surprise of 10.14%, on average. In the last reported quarter, Can-Fite BioPharma’s earnings beat estimates by 10.00%.